Lindbrook Capital’s XBiotech XBIT Stock Holding History

Lindbrook Capital’s Portfolio XBIT Stock Details XBIT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q3	–	Sell	-66	Closed	–	–	2941
2022 Q2	$0	Buy	+66	New	+$444	﹤0.01%	2805

Other funds holding XBIT

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

OMC

Oasis Management Company Grand Cayman, Cayman Islands $1.72B AUM 32.1% 1-Year Est. Return

BCM

Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Lindbrook Capital's XBIT Position: Q3 2022 in Review

Lindbrook Capital sold out of XBiotech (XBIT) in Q3 2022, closing a stake of 66 shares.

Lindbrook Capital first reported a position in XBIT in Q2 2022 and held it in 1 quarter. The position peaked at $0 in Q2 2022. 45 funds tracked by Wall St. Rank hold XBIT as of Q3 2022.

Lindbrook Capital reported no remaining XBiotech position as of Q3 2022 after selling out during the quarter.
Lindbrook Capital sold 66 XBiotech shares in Q3 2022.
Lindbrook Capital first reported a position in XBiotech in Q2 2022 and held it in 1 quarter.
Lindbrook Capital's XBiotech position peaked at $0 in Q2 2022.
45 funds tracked by Wall St. Rank held XBiotech as of Q3 2022.

Based on Lindbrook Capital's 13F filing for Q3 2022, filed 10 Nov 2022.